However, with the advance of targeted therapies such as BRAF and MEK inhibitors and immune checkpoint inhibitors (discussed in detail below), the utility and accuracy of the Sperduto GPA for determining the prognosis of patients with melanoma brain metastases will be altered and thus require additional revisions to remain a useful prognostic tool [130]. Here, BRAF is linked to melanoma.